The Journal of Pediatrics
Volume 155, Issue 3 , Pages 309-310 , September 2009

Missed Opportunities for Duchenne Muscular Dystrophy

  • Petra Kaufmann, MD, MSc

      Affiliations

    • Corresponding Author InformationReprint requests: Petra Kaufmann, MD, MSc, Columbia University, Department of Neurology, 180 Fort Washington Way, Harkness Pavilion Floor 5, New York, NY 10032.

References 

  1. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509–517
  2. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Disord. 2002;12:926–929
  3. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;CD003725
  4. Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855–857
  5. Hoffman EP, Beggs AH, Koenig M, et al. Cross-reactive protein in Duchenne muscle. Lancet. 1989;2:1211–1212
  6. Wagner KR. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics. 2008;5:583–591
  7. Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatrics. 2009;155:380–385

PII: S0022-3476(09)00248-0

doi: 10.1016/j.jpeds.2009.03.034

The Journal of Pediatrics
Volume 155, Issue 3 , Pages 309-310 , September 2009

Article Tools